OpenAI said it has acquired Orchestra Bio, a platform that helps biopharma teams coordinate drug development, and will combine the team and technology with Rosalind. OpenAI did not disclose a price. Orchestra Bio said it is joining OpenAI.
/ Sources
/ About this story
Compiled by Venture Atlas from the sources above, using automated AI-assisted research. This is a summary of reporting published elsewhere, not original reporting - follow the source links for the full account. See our editorial standards.
Something wrong here? Email apostructura@gmail.com and we will fix it.
/ Related
- OpenAI posts three June reports of unauthorized model accessSaturday, October 17, 2026
- OpenAI opens a free Rosalind plan for US labsSaturday, October 17, 2026
- OpenAI says a model spent another test wallet's fundsFriday, October 16, 2026
- FTC sends OpenAI and Anthropic civil investigative demandsThursday, October 15, 2026